Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes
Researchers found no clear explanation for the association between the use of canagliflozin and increased fracture risk in the CANVAS Program.
Fracture
Does Osteoporosis Treatment Reduce Overall Mortality in Addition to Fracture Risk?
The meta-analysis included 101,642 patients with osteoporosis.
Bone Health Essentials: Follow-Up After Breast and Prostate Cancer
Improved survival of patients with prostate and breast cancer has come at a cost. Clinicians need to be vigilant with preventive care for patients with these cancers to maintain their dental and bone health.
High Prevalence of Low BMD, Fragility Fractures 10 Years After Bariatric Surgery
More than a quarter of postmenopausal women and men ≥50 years of age were found to have osteoporosis a decade after undergoing Roux-en-Y gastric bypass surgery.
Abdominal Aortic Calcification May Indicate Higher Fracture Risk in Older Women
Older women with significant abdominal aortic calcification are more likely to experience incident clinical fractures.
FRAX Useful for Fracture Risk Assessment in Patients With Knee OA
The FRAX calculations showed higher probabilities of major osteoporotic fracture in patients with knee osteoarthritis vs healthy controls.
Increased Risk for Osteoporotic Fractures in Elderly After Gastrectomy
Fracture risk remained higher decades after surgery in men who underwent gastrectomy compared with patients who never underwent the procedure.
Frail Patients With Rheumatoid Arthritis May Experience More Osteoporotic Fractures
Researchers explored the association between frailty and the risk for osteoporotic fractures in patients with rheumatoid arthritis.
No Association Between DPP-4 Inhibitor, GLP-1 Receptor Agonist, SGLT2 Inhibitor Use and Fracture Risk
Researchers found no association between the use of DPP-4 inhibitors, GLP-1 receptor agonists, or SGLT2 inhibitors and the risk for fracture in patients with type 2 diabetes.
Long-Term Denosumab Treatment Reduces Nonvertebral Fractures in Osteoporosis
Compared with the first 3 years of denosumab treatment, a longer duration of denosumab therapy was associated with further decrease in nonvertebral fracture rate, which was sustained through 10 years of treatment.
Next post in Bone Metabolism
